tokajo schreef op 5 september 2019 12:12:
Ik had graag beter nieuws gepost, maar dit ziet er niet goed uit. Opgen zit nog veel dieper in de shit dan Curetis.
Problemen met de notering:
www.sec.gov/Archives/edgar/data/12938...Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On August 19, 2019, OpGen, Inc. (the “Company”), received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it fails to comply with Nasdaq’s Marketplace Rule 5550(b)(1) because the Company’s stockholders’ equity as of June 30, 2019 fell below the required minimum of $2,500,000 and as of June 30, 2019, the Company did not meet the alternative compliance standards of market value of listed securities or net income from continuing operations for continued listing.
In accordance with Nasdaq’s listing requirements, the Company has 45 calendar days to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant the Company an extension of up to 180 calendar days from the date it received the notification to evidence compliance.
The Company intends to promptly evaluate various courses of action to regain compliance and to timely submit a plan to Nasdaq to regain compliance with the Nasdaq minimum stockholders’ equity standard. However, there can be no assurance that the Company’s plan will be accepted or that if it is, the Company will be able to regain compliance.
Problemen met de cash:
seekingalpha.com/news/3496066-opgen-1...A capital raise appears likely since this will be the way the company will increase stockholders' equity (additional paid-in capital). At the end of June, it had $3.1M in cash and equivalents while operations consumed ($5.8M) in H1.
En ik denk dat de oplossing ten koste gaat van de aandeelhouders van Curetis. Dit gezien het laatste item in de "Conditions to closing".
ir.opgen.com/news-releases/news-relea...Conditions to Closing
The Closing is subject to (i) the satisfaction of customary conditions to closing for a transaction of this type, including the absence of a material adverse event for either party, (ii) for each of OpGen and Curetis, appropriate approvals by their respective shareholders, (iii) for Curetis, consents from certain debt financing providers, (iv) the Form S-4 having been declared effective by the U.S. Securities and Exchange Commission, (v) the new shares of OpGen’s common stock to be issued (or reserved for issuance) in connection with the transaction having been approved for listing on Nasdaq and (vi) OpGen having secured additional funding prior to Closing.